# Virginia Paton

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/virginia-paton/

## Facts

| Field | Value |
| --- | --- |
| Citations | 18,328 |
| Field | HER2/EGFR in Cancer Research |
| h-index | 21 |
| i10-index | 26 |
| Last Known Institution | Kaiser Permanente San Francisco Medical Center |
| OpenAlex ID | https://openalex.org/A5013134881 |
| ORCID iD | https://orcid.org/0000-0002-3912-9050 |
| Works | 41 |

## Researcher papers

- [Use of Chemotherapy plus a Monoclonal Antibody against HER2 for Metastatic Breast Cancer That Overexpresses HER2](https://scholariq.org/papers/use-of-chemotherapy-plus-a-monoclonal-antibody-against-her2-for-metastatic/)
- [Cardiac Dysfunction in the Trastuzumab Clinical Trials Experience](https://scholariq.org/papers/cardiac-dysfunction-in-the-trastuzumab-clinical-trials-experience/)
- [Results From the Phase III Randomized Trial of Onartuzumab Plus Erlotinib Versus Erlotinib in Previously Treated Stage IIIB or IV Non–Small-Cell Lung Cancer: METLung](https://scholariq.org/papers/results-from-the-phase-iii-randomized-trial-of-onartuzumab-plus-erlotinib-versus/)

## Researcher topics

- [HER2/EGFR in Cancer Research](https://scholariq.org/topics/her2-egfr-in-cancer-research/)
- [Monoclonal and Polyclonal Antibodies Research](https://scholariq.org/topics/monoclonal-and-polyclonal-antibodies-research/)
- [Cancer Immunotherapy and Biomarkers](https://scholariq.org/topics/cancer-immunotherapy-and-biomarkers/)
- [Cancer Treatment and Pharmacology](https://scholariq.org/topics/cancer-treatment-and-pharmacology/)
- [Peptidase Inhibition and Analysis](https://scholariq.org/topics/peptidase-inhibition-and-analysis/)

## Researcher university

- [Kaiser Permanente San Francisco Medical Center](https://scholariq.org/institutions/kaiser-permanente-san-francisco-medical-center/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.